|
|
|
|
|
|
|
11.06.26 - 12:01
|
Bayer Aktie: Finale im Glyphosat- Rechtsstreit? (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Bayer-Aktienanalyse der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie der Bayer AG (ISIN: DE000BAY0017, WKN: BAY001, Ticker-Symbol: BAYN, NASDAQ OTC-Symbol: BAYZF) unter die Lupe. [mehr]...
|
|
|
11.06.26 - 11:24
|
EMA validates Bayer′s asundexian application for ischaemic stroke (PBR)
|
|
|
EMA has now begun reviewing its use in adults following a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). The validation confirms the application is complete
The post EMA validates Bayer's asundexian application for ischaemic stroke appeared first on Pharmaceutical Business review....
|
|
|
10.06.26 - 14:06
|
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines (Business Wire)
|
|
|
Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors
Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD)
SAN FRANCISCO--(BUSINESS WIRE)--#biotech--SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.
The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Ventur...
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 08:39
|
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche....
|
|
|
09.06.26 - 18:15
|
Bayer-Aktie: Setzt sich der Abwärtstrend fort? (Sharedeals)
|
|
|
Die Bayer-Aktie kommt weiter nicht nachhaltig vom Fleck. Nach der Erholung der vergangenen Monate hat sich der kurzfristige Abwärtsdruck wieder verstärkt, während die saisonale Auswertung für die kommenden Monate ebenfalls zur Vorsicht mahnt. Damit rücken nun klare Kursmarken in den Fokus. Tendenzielle Schwäche voraus Die Bayer-Aktie hat zuletzt erneut Schwäche gezeigt und notiert inzwischen wieder […]
The post Bayer-Aktie: Setzt sich der Abwärtstrend fort? first appeared on sharedeals.de....
|
|
|
09.06.26 - 15:45
|
Bayer-Aktie: Was verspricht die zweite Jahreshälfte? (Sharedeals)
|
|
|
Die Bayer-Aktie bleibt auch im Juni 2026 einer der umstrittensten Werte im DAX. Nach einer starken Erholung im vergangenen Jahr steht das Papier zuletzt wieder unter Druck und notiert aktuell im Bereich von rund 35 Euro. Damit liegt die Aktie deutlich unter ihrem 52-Wochen-Hoch von knapp 50 Euro. Belastend wirken vor allem die anhaltenden Rechtsstreitigkeiten […]
The post Bayer-Aktie: Was verspricht die zweite Jahreshälfte? first appeared on sharedeals.de....
|
|
|
09.06.26 - 15:03
|
Up Capital Management Appoints Nyle Bayer as CEO (Business Wire)
|
|
|
Multigenerational succession at the Roseville-based RIA. Founder Anton Bayer, CFP®, transitions to Chairman and Chief Investment Officer.ROSEVILLE, Calif.--(BUSINESS WIRE)--Up Capital Management, an independent registered investment advisor managing more than $200 million in client assets, today announced the appointment of Nyle Bayer as Chief Executive Officer. The move marks a multigenerational succession at the firm, with founder Anton Bayer, CFP®, transitioning to Chairman and Chief Investment Officer.
Nyle Bayer steps in with two priorities. First, to expand the firm's service offerings from financial planning and investment management to a full suite of financial, behavioral, investment, estate, tax, and compensation planning services. The second is to build an organic growth engine that connects prospective clients with the right advisor relationship.
With more than a decade of senior leadership across wealth management, asset management, and wealthtech, Nyle Bayer brings a rare combination of s...
|
|
|
|
|
09.06.26 - 08:24
|
Bayer Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Bayer mit einem Kursziel von 52 Euro auf "Buy" belassen. Das Expertengespräch habe die Komplexität und die Risiken für den Glyphosat-Vergleich unterstrichen, schrieb Matthew ......
|
|
|
08.06.26 - 14:03
|
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth (Business Wire)
|
|
|
BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the company's commitment to continuously adapt and advance its Road to Billions strategy aimed at helping billions of people live healthier lives.
As part of these changes, Bayer has appointed new global leaders across the Marketing, Insights & Analytics, and Commercial Operations functions and named a new Consumer Health President for the United States, its largest Consumer Health market.
Key leadership appointments include:
Samantha Avivi appointed global Chief Marketing Officer (CMO), Consumer Health
Will lead global brand building, marketing, and consumer strategy
Joins the global Consumer Health Leadership Team
Based in Whippany, NJ, United States
Analia de la Fuente appointed global Chief Data Officer (CDO), Consumer Health
Will lead insights and an...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
